CDDO-Im

Cat. No.: 0225LY-0909

Appearance: Solid

Purity: ≥99%

Identity: Confirmed by NMR, HPLC, and LC-MS.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: CDDO-Im serves as an activator for both Nrf2 and PPAR receptors, with Ki values of 232 nM for PPARα and 344 nM for PPARγ.

Synonym: RTA-403; CDDO-Imidazolide; TP-235; 443104-02-7; (4aR,6aR,6aS,6bR,8aS,12aS,14bS)-8a-(imidazole-1-carbonyl)-4,4,6a,6b,11,11,14b-heptamethyl-3,13-dioxo-4a,5,6,6a,7,8,9,10,12,12a-decahydropicene-2-carbonitrile; (4aR,6aS,6bR,8aS,12aS,12bR,14bS)-8a-(1H-imidazole-1-carbonyl)-4,4,6a,6b,11,11,14b-heptamethyl-3,13-dioxo-3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-octadecahydropicene-2-carbonitrile; SMR001566062; 1-(2-Cyano-3,12,28-trioxooleana-1,9(11)-dien-28-yl)-1H-imidazole; 2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid imidazolide

CAS No.: 443104-02-7

Compound CID: 9958995

Formula: C₃₄H₄₃N₃O₃

Formula Weight: 541.72

Specification

Targets&IC50: PPARγ: 344 nM (Ki); PPARα: 232 nM (Ki)

Relative Density: 1.23 g/cm³

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: CDDO-Im can be used in cancer biology research to investigate the induction of Phase 2 detoxifying enzymes and their anti-proliferative activities.